Less than a tenth of patients that would benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it issues its first guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a long-term condition that can be managed with thorough and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant obstacles to universal availability to the injections that can help people shift considerable body mass, explains the organization.
Skinny Jab Scarcity
Even under the current most optimistic case, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The guideline urges nations and manufacturers to increase access, by approaches such as patent sharing.
Exclusive production rights on the active ingredient – the main component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Jabs Operate
The injections mimick a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so users eat less.
People typically begin shedding pounds within a few weeks of commencing the regular doses.
Studies indicates patients may see weight return a year later of halting the treatment, because their normal food cravings come back.
To be above a healthy weight elevates your chance for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
